Hand and foot eczema cleared or nearly cleared in 53% of patients treated with Eli Lilly's Ebglyss (lebrikizumab), versus 27% on placebo, Medical Daily reported this week.

The roughly twofold separation positions the IL-13-directed monoclonal antibody as a candidate for palmoplantar atopic dermatitis — a distribution where thickened skin on the palms and soles often responds poorly to topical therapy and where no biologic currently carries a targeted indication.

Why does hand and foot eczema need a systemic option?

Palmoplantar atopic dermatitis affects the palms, soles, and lateral aspects of the fingers and toes. Hyperkeratosis, fissuring, and chronic itch interfere with grip, gait, and manual work.

The thickened stratum corneum limits topical drug penetration. Standard of care runs through high-potency topical corticosteroids and topical calcineurin inhibitors, with systemic options reserved for refractory disease.

What did the comparison show?

The headline figures translate to the Investigator's Global Assessment (IGA):

• Active arm (Ebglyss): 53% reached IGA 0/1.
• Placebo arm: 27% reached IGA 0/1.
• Absolute difference: 26 percentage points.
• Relative risk: approximately 2.0.

The active-versus-placebo split mirrors the magnitude seen across Ebglyss's pivotal program in moderate-to-severe atopic dermatitis, where IGA 0/1 responses at week 16 ran in a comparable band against placebo.

How does Ebglyss work?

Lebrikizumab is a subcutaneous monoclonal antibody that selectively binds interleukin-13 (IL-13), a type-2 cytokine driving pruritus, epidermal barrier disruption, and the Th2-skewed inflammation characteristic of atopic dermatitis.

By blocking IL-13, the drug spares IL-4 signaling through the type I receptor — a mechanistic distinction Lilly has emphasized versus dual IL-4/IL-13 inhibitors such as dupilumab.

Where Ebglyss stands today

Regulators in the United States, European Union, and Japan have cleared Ebglyss for moderate-to-severe atopic dermatitis in adults and adolescents, typically as a later-line option after topical prescription therapy has failed.

A hand-and-foot-specific label would expand the eligible population and address a documented unmet need, since palmoplantar disease is over-represented among patients who escalate from topical therapy to systemic agents.

What the palmoplantar signal could mean for Lilly

The 53% figure makes a label-expansion case for Ebglyss in palmoplantar disease if Lilly pursues the indication. Clinicians tracking a hand-and-foot-specific approval will be watching for:

• The full publication or congress presentation, including trial name, sample size, and primary timepoint.
• Baseline severity stratification, since palmoplantar cohorts can include both moderate and severe recalcitrant disease.
• Safety signals in the hand/foot subset, particularly given the drug's class-typical conjunctivitis and injection-site reaction profile.

The next milestone will be whether the FDA, EMA, and Japan's PMDA accept palmoplantar data as label-supportive or require a dedicated trial before granting a hand-and-foot-specific indication.